ATORX — Alligator Bioscience AB Share News
0.000.00%
Last trade - 00:00- SEK105.65m
- SEK105.06m
- SEK0.51m
Brief: Alligator Bioscience Reports Survival Benefit & Long Response Duration from Mitazalimab Phase 2 Study in First-Line Pancreatic Cancer
Brief: Alligator Bioscience: Primary Endpoint Of Optimize-1 Trial Was Met
Brief: Alligator Bioscience Appoints Johan Giléus As CFO
Brief: Alligator Bioscience Says Henlius Biotech Gets FDA IND Clearance For Phase 3 Initiation To Evaluate HLX22 (Ac101) In 1st Line HER2+ Advanced Gastric Cancer
Brief: Alligator Bioscience Q1 EBIT SEK -59.636 Million
Brief: Alligator And Orion Develop Option Under 2021 Collaboration And License Agreement
Brief: Alligator Raises About SEK 107.1 Mln In Rights Issue
Brief: Alligator Bioscience, Aptevo Therapeutics Announce Positive Interim Data Of Dose Escalation Phase Of ALG.APV-527 Phase 1 Study
Brief: Alligator Carries Out Units Rights Issue, Bridge Loans
Brief: Alligator Bioscience Announces Cost Reduction Program
Brief: Alligator Bioscience Announces Positive Mitazalimab Optimize-1 Phase 2 Results
Brief: Alligator Bioscience Gets Granted U.S. Patent For Cancer Treatment Antibody
Brief: Alligator Bioscience Q3 Operating Result Turns To Loss of SEK 52.7 Mln
Brief: Alligator Gets About SEK 13.8 Million Through Exercise Of Warrants
Brief: Alligator Bioscience Receives EMA Orphan Designation For Mitazalimab
Brief: Alligator Bioscience Q2 EBIT Loss at SEK 63.7 Million
Brief: Alligator Bioscience: Positive 2nd Interim Efficacy Analysis From Mitazalimab Optimize-1 Phase 2 Study In 1st Line Pancreatic Cancer
Brief: Alligator Bioscience, Orion Corporation Announce Exercise Of Development Option
Brief: Alligator Bioscience Posts Q1 Net Loss of SEK 62.5 Million